DB-1310 by Duality Biologics (Shanghai) for Solid Tumor: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Solid Tumor.

Using AI to Predict Exacerbations in Uncontrolled COPD

Artificial intelligence (AI) and natural language processing tools can build an algorithm that identifies patients with chronic obstructive pulmonary disease (COPD) at risk for exacerbations,

November 2, 2023

New study identifies 4,749 key gene clusters that influence progression of 32 cancer types

Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly

November 14, 2023

GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025

GSK said it is on track to convert its global manufacturing sites into using renewable electricity, with its facilities in Singapore becoming the latest to

June 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.